Regentis Appoints CFO To Lead Commercialization

Regentis Biomaterials appointed Ori Gon as chief financial officer and chief business officer on Feb. 4 to lead financial strategy and commercial development as its lead product GelrinC nears commercial launch in Europe and advances through a pivotal U.S. Phase III trial. GelrinC is a CE-marked, cell-free hydrogel implant for focal knee cartilage repair marketed as a cost-effective, 10-minute procedure with faster recovery and sustained pain relief.